LLY · 10-Q · 2026Q1

ELI LILLY & Co

Filed 2026-04-30 · Healthcare · View original filing on EDGAR

Ranked Events

• Acquisition Activity and IPR&DImportance 96 · Surprise 100
  The company has entered into acquisition agreements in 2026 that remain subject to customary closing conditions. Potential amounts payable at closing for these pending acquisitions would be up to approximately $12…
• Product Revenue - Mounjaro and ZepboundImportance 96 · Surprise 100
  Mounjaro net product revenue totaled $8,662 million for the three months ended March 31, 2026 (U.S. $4,232 million; Outside U.S. $4,430 million) versus $3,842 million in the prior-year quarter. Zepbound net product…
• Revenue Performance and MixImportance 96 · Surprise 100
  Consolidated revenue for the three months ended March 31, 2026 was $19,799 million versus $12,729 million in the prior-year quarter, an increase of $7,070 million. U.S. revenue was $12,119 million and Outside U.S.…
• Geographic revenue shift - China NRDLImportance 89 · Surprise 82
  Outside the U.S., revenue growth was driven primarily by Mounjaro, with lower realized prices principally attributable to Mounjaro's addition to China's National Reimbursed Drug List (NRDL). Revenue outside the U.S.…
• Operating Expense TrendsImportance 73 · Surprise 66
  Research and development expense was $3,510 million for the three months ended March 31, 2026 versus $2,734 million in the prior-year quarter, an increase of 28% driven by continued investments in the early and…
• Acquisition Commitments $12BImportance 71 · Surprise 60
  Lilly disclosed that as part of its 2026 business development activities it has entered into acquisition agreements subject to closing conditions. Potential amounts payable at closing for these pending acquisitions…
• Incretin Revenue ConcentrationImportance 71 · Surprise 60
  Mounjaro and Zepbound accounted for 65 percent of Lilly's total revenue for the three months ended March 31, 2026, making cardiometabolic/incretin products a dominant contributor to near-term results. Lilly received…
• Incretin product concentrationImportance 71 · Surprise 60
  Mounjaro and Zepbound together accounted for 65% of Lilly's total revenue for the three months ended March 31, 2026, making cardiometabolic/incretin products the dominant revenue driver. The company notes FDA approval…
• Market Demand TrendsImportance 69 · Surprise 64
  Consolidated revenue rose to $19.8 billion for the three months ended March 31, 2026, driven primarily by increased volume but partially offset by lower realized prices. Volume growth was concentrated in Mounjaro and…
• Inflation Reduction Act ImpactImportance 65 · Surprise 60
  Lilly identifies the Inflation Reduction Act of 2022 (IRA) as requiring HHS to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. HHS selections included…
• U.S. GLP-1 Bridge ProgramImportance 65 · Surprise 60
  In Q1 2026 Lilly finalized voluntary agreements with the U.S. government that include lowering Medicaid and certain other drug prices for U.S. patients and launch commitments with a more balanced pricing approach…
• Revenue Concentration RiskImportance 64 · Surprise 42
  Mounjaro and Zepbound together accounted for 65 percent of total revenue for the three months ended March 31, 2026. The company states cardiometabolic health products will continue to represent a significant and…
• Pricing pressure and competitionImportance 63 · Surprise 64
  Zepbound revenue in the U.S. increased 79% year-over-year driven by strong demand, but lower realized prices (including previously announced reductions in cash-pay prices) moderated revenue growth. Across products,…
• Outstanding IndebtednessImportance 61 · Surprise 32
  As of March 31, 2026, Lilly reported total debt of $43.4 billion, an increase of $0.9 billion from $42.5 billion as of December 31, 2025. The company refers readers to Note 7 for additional details on maturities and…
• Outstanding Indebtedness and Credit FacilitiesImportance 61 · Surprise 32
  Total debt was $43.4 billion as of March 31, 2026, an increase of $0.9 billion from $42.5 billion at December 31, 2025. The company reported $10.1 billion of unused committed bank credit facilities as of March 31,…
• Liquidity and Cash PositionImportance 59 · Surprise 48
  Cash and cash equivalents decreased to $5.3 billion as of March 31, 2026 from $7.3 billion as of December 31, 2025. Lilly held total investments of $3.3 billion as of March 31, 2026 and had approximately $850 million…
• Pricing and Reimbursement PressureImportance 58 · Surprise 42
  Lilly identifies global concerns around access and affordability driving governmental cost containment efforts, including mandated discounts, price reporting, reference pricing, restrictive formularies, and changes to…
• Regulatory Compliance / Manufacturing RiskImportance 58 · Surprise 42
  Lilly describes regulatory issues around compliance with current Good Manufacturing Practices, quality assurance, safety signals, evolving standards, and scrutiny of excipients and potential impurities (e.g.,…
• Capital Return ProgramImportance 56 · Surprise 24
  During the three months ended March 31, 2026, Lilly repurchased $2.3 billion of shares under its $15.0 billion repurchase program authorized in December 2024 and had $8.6 billion remaining under the program as of March…
• Product / Drug Pipeline ProgressImportance 53 · Surprise 60
  Orforglipron (Foundayo) received FDA approval for the treatment of obesity and a Phase 3 trial for orforglipron in type 2 diabetes met its primary endpoint. Multiple Phase 3 trials were initiated in the period,…

Revenue by Product (in millions)

Revenue by Geography (in millions)